公开(公告)号：US20110236454A1

公开(公告)日：2011-09-29

申请号：US13074212

申请日：2011-03-29

Applicant: Joram Slager

Inventor： Joram Slager

IPC: A61F13/00 ,  A61K9/00 ,  A61K38/00 ,  A61K31/7088 ,  A61K47/30 ,  A61K47/36 ,  A61P27/06 ,  A61P27/12 ,  A61P3/10 ,  A61P31/00 ,  A61P31/10 ,  A61P31/12 ,  A61P35/00

CPC classification number: A61K9/0024 ,  A61F9/00 ,  A61K9/0051 ,  A61K9/06 ,  A61K47/36 ,  C08B30/18 ,  C08B31/006 ,  C08J3/075 ,  C08J2305/00

Abstract: The invention provides an injectable formulation that includes an active agent; a biocompatible solvent system, crosslinkable polymers such as polysaccharides; and crosslinking agents; wherein the formulation is substantially free of water. The invention also provides a drug delivery depot formed from the injectable formulation wherein the polymers crosslink in the presence of water in the body of a patient, or in the air, prior to implantation in the patient. Also provided are methods of treatment using such formulations and drug delivery systems.

Abstract translation: 本发明提供了包含活性剂的可注射制剂; 生物相容性溶剂体系，可交联聚合物如多糖; 和交联剂; 其中所述制剂基本上不含水。 本发明还提供由可注射制剂形成的药物递送贮库，其中在植入患者之前，聚合物在患者身体或空气中的水存在下交联。 还提供了使用这种制剂和药物递送系统的治疗方法。

公开(公告)号：US20100303879A1

公开(公告)日：2010-12-02

申请号：US12792365

申请日：2010-06-02

Applicant: Aleksey V. Kurdyumov ,  Nathan A. Lockwood ,  Joram Slager ,  Dale G. Swan ,  Robert Hergenrother

Inventor： Aleksey V. Kurdyumov ,  Nathan A. Lockwood ,  Joram Slager ,  Dale G. Swan ,  Robert Hergenrother

IPC: A61K8/73 ,  C08L71/00 ,  B32B9/02

CPC classification number: A61K39/39591 ,  A61L17/005 ,  A61L17/145 ,  A61L27/34 ,  A61L27/54 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/256 ,  A61L2300/624 ,  C07K2317/55 ,  Y10T428/31663 ,  C08L71/02 ,  C08L67/04

Abstract: Silane-functionalized hydrophobic α(1→4)glucopyranose polymers and polymeric matrices are described. Biodegradable matrices can be formed from hydrophobic α(1→4)glucopyranose polymers with reactive pendent silyl ether groups. Reaction of the silyl ether groups provides improved matrix formation through bonding to a device surface of a device, polymer-polymer crosslinking, or both. Biodegradable matrices can be used for the preparation of implantable and injectable medical devices, including those that release a bioactive agent.

Abstract translation: 描述了硅烷官能化的疏水性α（1→4）吡喃葡萄糖聚合物和聚合物基质。 生物可降解基质可以由具有反应性侧挂甲硅烷基醚基团的疏水性α（1→4）吡喃葡萄糖聚合物形成。 甲硅烷基醚基团的反应通过结合到器件的器件表面，聚合物 - 聚合物交联或两者来提供改进的基质形成。 可生物降解基质可用于制备可植入和可注射的医疗器械，包括那些释放生物活性剂的医疗器械。

公开(公告)号：US20100260846A1

公开(公告)日：2010-10-14

申请号：US12756632

申请日：2010-04-08

Applicant: Joseph Schmidt McGonigle ,  Joram Slager

Inventor： Joseph Schmidt McGonigle ,  Joram Slager

IPC: A61K9/14 ,  A61K31/7088 ,  A61K47/48 ,  B05D7/00

CPC classification number: A61K9/1641 ,  A61K9/0024 ,  A61K9/1647 ,  A61K9/5084 ,  A61K48/0041 ,  A61L17/005 ,  A61L17/12 ,  A61L27/48 ,  A61L27/54 ,  A61L29/126 ,  A61L29/148 ,  A61L31/129 ,  A61L31/16 ,  A61L2300/258 ,  A61L2300/62 ,  C12N15/89 ,  C08L67/04

Abstract: Embodiments of the invention include devices and methods for the release of nucleic acid complexes. In an embodiment the invention includes a nucleic acid delivery particle. The delivery particle can include a polymeric matrix including a polyethyleneglycol containing copolymer and a nucleic acid complex disposed within the polymeric matrix. The nucleic acid complex can include a nucleic acid and a carrier agent. In an embodiment the invention includes a medical device including a first polymeric matrix comprising a first polymer and a plurality of nucleic acid delivery particles disposed within the first polymeric matrix. The medical device can be configured to release the nucleic acid complex when the medical device is implanted within a subject. Other embodiments are included herein.

Abstract translation: 本发明的实施方案包括用于释放核酸复合物的装置和方法。 在一个实施方案中，本发明包括核酸递送颗粒。 递送颗粒可以包括聚合物基质，其包含含聚乙二醇的共聚物和设置在聚合物基质内的核酸复合物。 核酸复合物可以包括核酸和载体试剂。 在一个实施方案中，本发明包括医疗装置，其包括第一聚合物基质，其包含第一聚合物和设置在第一聚合物基质内的多个核酸递送颗粒。 医疗装置可被配置为当将医疗装置植入受试者内时释放核酸复合物。 本文还包括其它实施例。